https://www.selleckchem.com/products/tasin-30.html
The prevalence and types of fibroblast growth factor receptor ( ) mutations vary significantly among different ethnic groups. The optimal application of FGFR inhibitors depends on these variations being comprehensively understood. However, such an analysis has yet to be conducted in Chinese patients. We retrospectively screened the genomic profiling results of 10,582 Chinese cancer patients across 16 cancer types to investigate the frequency and distribution of aberrations. aberrations were identified in 745 patients, equating to an ov
Like
Comment
Share
